生物分析检测服务市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球生物分析测试服务市场预计将从 2025 年的 50.1 亿美元成长到 2031 年的 68.3 亿美元，复合年增长率为 5.31%。

这些服务涉及对生物系统中药物、代谢物和生物标记的定量测量，对于支持药物研发整体的药物动力学和毒代动力学研究至关重要。推动该市场成长要素是药物研发成本的不断攀升，以及开发需要严格安全检验的复杂生物製药和生物相似药的需求。根据欧洲製药工业协会联合会（EFPIA）预测，到2024年，以研发为基础的製药业预计将在欧洲的研发领域投入约550亿欧元，这笔巨额资金将用于支持日益增长的外包检测需求，以确保不断扩大的药物研发管线符合监管要求。

然而，由于能够执行先进分析方法的专业人员短缺，这项市场扩张面临巨大的挑战。大分子检测所需的复杂性要求具备质谱和配体结合等技术的专业知识。合格人员的短缺造成了营运瓶颈和计划进度延误，限制了服务供应商充分利用研发活动成长的机会。

市场驱动因素

生物製剂和生物相似药开发平臺的快速扩张显着提升了对专业生物分析检测服务的需求。随着製药公司日益重视大分子药物而非传统的小分子化合物，对复杂免疫抗原性检测和药物动力学分析的需求也显着增加。这种转变要求分析平台能够表征复杂的蛋白质结构，并确保其安全性符合严格的核准标准。根据美国食品药物管理局（FDA）于2024年1月发布的《2023年新药核准情况报告》，该机构已核准55种新疗法，这一数字凸显了加速药物创新和全面实验室检验以支持多元化开发平臺的必要性。

同时，全球临床试验数量和复杂性的快速成长是推动生物分析服务普及的关键因素。现代临床研究越来越多地涉及多区域检测点和分层患者群体，这需要统一的检测通讯协定来高效处理海量的生物检体。日益增长的营运负担迫使申办方依赖外部合作伙伴提供的高通量生物分析服务来维护研究的完整性。根据美国国家医学图书馆2024年5月发布的「趋势、图表和地图」更新报告，ClinicalTrials.gov网站上註册的临床试验累积数量已达492,996项，凸显了需要支持的研究活动规模之庞大。此外，这种外包趋势的经济影响也反映在主要服务供应商的业绩上。例如，Icon Plc在2024年2月公布的年收入为81.202亿美元，反映出整个产业对受託研究机构（CRO）的依赖，以应对这些高强度的检测需求。

市场挑战

合格人员短缺是全球生物分析检测服务市场成长的主要障碍。随着药物研发转向复杂的生物製药和生物相似药，对先进分析检测的需求呈现爆炸性成长。然而，这些分子所需的复杂检测方法需要具备质谱和配体结合等复杂调查方法专业知识的技术人员。当服务供应商缺乏具备这些特定技能的人员时，他们就无法有效率地处理大量样本，造成营运瓶颈。这会导致计划交付时间延长，并阻碍合约研究组织 (CRO) 满足严格的监管时限要求。

人才短缺直接阻碍了市场吸收日益增长的外包研究的能力。如果人员不足，测试机构将无法扩大规模以跟上药物研发的步伐，迫使它们推迟研究启动并拒绝新契约。据英国製药工业协会和生物产业协会称，生命科学产业将在2025年面临关键压力点，到2035年，还需要新增7万个工作机会才能满足产业需求。预期的人才短缺凸显了日益扩大的技能差距，阻碍了服务供应商充分利用现有资本投资，从而减缓了市场整体扩张的步伐。

市场趋势

由于细胞和基因疗法具有独特的技术要求，全球生物分析检测服务市场目前正经历细胞和基因疗法分析服务的激增。这些治疗方法与标准生物製药有着本质差异。与单株抗体不同，细胞和基因疗法需要进行专门的检测，以表征病毒载体、转导效率和长期基因组稳定性，这迫使服务供应商投资建造专用的高等级生物安全检测基础设施。该行业的成熟度和财务韧性正在推动对这些专业服务的需求。根据再生医学联盟发布的《2025年1月产业趋势简报》，细胞和基因治疗领域的投资正在以30%的速度增长，而这笔巨额资金的涌入直接推动了对复杂生物分析验证的需求，以支持不断扩大的开发平臺。

同时，随着製药策略向精准医疗和患者分层转型，生物标记和伴随诊断检测的扩展正在重塑市场格局。这一趋势迫使生物分析实验室超越传统的药物动力学检测，整合高灵敏度的生物标记检验平台，并与临床试验同步开发诊断测试。这种转变带来的业务扩张在主要产业参与者的表现中清晰可见。根据Labcorp于2025年2月发布的截至2024年12月31日的年度报告，该公司生物製药实验室服务部门（涵盖中心实验室和生物标誌物功能）的收入达到29.226亿美元，年增5.3%，这主要得益于市场对这些复杂分析服务的自然增长需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球生物分析检测服务市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（基于细胞的检测、细菌细胞检测、病毒细胞检测、病毒学检测、体外病毒学检测、体内病毒学检测、物种特异性病毒PCR检测方法开发、优化和检验、血清学、免疫抗原性和中和抗体、生物标记检测、药物动力学检测、其他服务）
  • 依应用领域（肿瘤学、神经病学、感染疾病、胃肠病学、心臟病学、其他应用领域）
  • 按最终用户（製药/生物製药公司、合约开发和生产组织、受託研究机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美生物分析检测服务市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲生物分析检测服务市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区生物分析检测服务市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲生物分析检测服务市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲生物分析检测服务市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球生物分析侦测服务市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• ICON plc
• Charles River Laboratories International, Inc.
• Covance, Inc.（Labcorp Drug Development）
• IQVIA Inc
• Syneos Health Inc
• SGS SA
• Intertek Group Plc
• Pace Analytical Services, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Bioanalytical Testing Services Market is projected to grow from USD 5.01 Billion in 2025 to USD 6.83 Billion by 2031, expanding at a CAGR of 5.31%. These services, which involve the quantitative measurement of drugs, metabolites, and biomarkers in biological systems, are essential for supporting pharmacokinetics and toxicokinetics studies throughout drug development. The market is primarily driven by rising pharmaceutical research expenditures and the need to develop complex biologics and biosimilars that require rigorous safety validation. According to the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry invested approximately €55,000 million in R&D in Europe during 2024, a significant financial commitment that underpins the increasing demand for outsourced testing to ensure regulatory compliance for expanding drug pipelines.

However, this market expansion faces significant challenges due to a shortage of skilled professionals capable of executing advanced analytical methodologies. The complexity of assays required for large molecules necessitates specialized expertise in techniques such as mass spectrometry and ligand binding. A scarcity of qualified personnel leads to operational bottlenecks and delays in project timelines, limiting the ability of service providers to fully capitalize on the growing volume of research activities.

Market Driver

The rapid expansion of biologics and biosimilars development pipelines significantly reinforces the demand for specialized bioanalytical testing services. As pharmaceutical companies increasingly prioritize large molecule therapeutics over traditional small molecules, there is a substantial rise in the requirement for intricate immunogenicity testing and pharmacokinetic assays. This transition necessitates analytical platforms capable of characterizing complex protein structures and ensuring safety profiles meet rigorous standards for approval. According to the U.S. Food and Drug Administration's 'Novel Drug Approvals for 2023' report released in January 2024, the agency approved 55 novel therapeutics, a figure that underscores the accelerating pace of drug innovation and the consequential need for comprehensive laboratory validation to support these diverse pipelines.

Concurrently, the surge in global clinical trial volume and complexity acts as a critical driver for bioanalytical service adoption. Modern clinical studies increasingly involve multi-regional sites and stratified patient populations, requiring harmonized testing protocols to efficiently process vast quantities of biological samples. This escalating operational burden compels sponsors to rely on external partners for high-throughput bioanalysis to maintain study integrity. According to the National Library of Medicine's 'Trends, Charts, and Maps' update in May 2024, the cumulative number of registered clinical studies on ClinicalTrials.gov reached 492,996, highlighting the immense scale of research activities requiring support. Furthermore, the financial magnitude of this outsourcing trend is evident in the performance of major service providers; Icon Plc, for instance, reported a full-year revenue of $8,120.2 million in February 2024, reflecting the industry-wide reliance on contract research organizations to manage these intensive testing requirements.

Market Challenge

The scarcity of qualified personnel poses a substantial barrier to the growth of the global bioanalytical testing services market. As pharmaceutical development shifts toward complex biologics and biosimilars, the demand for advanced analytical testing has surged. However, the sophisticated assays required for these molecules demand technicians with specialized expertise in intricate methodologies like mass spectrometry and ligand binding. When service providers lack a workforce with these specific competencies, they struggle to process sample volumes efficiently, creating operational bottlenecks that extend project turnaround times and compromise the ability of contract research organizations to meet rigorous regulatory timelines.

This workforce constraint directly impedes the market's capacity to absorb the rising volume of outsourced research. Without adequate staffing, testing facilities cannot scale operations to match the pace of drug discovery, forcing them to delay study initiations or decline new contracts. According to the Association of the British Pharmaceutical Industry and the BioIndustry Association, the life sciences sector faces a critical pressure point in 2025, where an additional 70,000 jobs will be required by 2035 to meet industry demand. This projected shortfall highlights a widening skills gap that restricts service providers from fully leveraging available capital investments, thereby slowing the overall trajectory of market expansion.

Market Trends

The Global Bioanalytical Testing Services Market is currently experiencing a surge in cell and gene therapy analytical services, driven by the unique technical requirements of these advanced modalities which differ fundamentally from standard biologics. Unlike monoclonal antibodies, cell and gene therapies require specialized testing for viral vector characterization, transduction efficiency, and long-term genomic stability, compelling service providers to invest in dedicated, high-containment testing infrastructures. The maturation and financial resilience of this sector are accelerating these specialized service needs; according to the Alliance for Regenerative Medicine's 'State of the Industry Briefing' in January 2025, investment in the cell and gene therapy sector rose by 30 percent, a significant capital influx that directly fuels the demand for intricate bioanalytical validation to support expanding development pipelines.

Concurrently, the market is defined by the expansion of biomarker and companion diagnostic testing as pharmaceutical strategies increasingly pivot toward precision medicine and patient stratification. This trend forces bioanalytical laboratories to evolve beyond traditional pharmacokinetic assays, requiring the integration of high-sensitivity platforms for biomarker validation and the co-development of diagnostic assays that run parallel to clinical studies. The operational growth resulting from this shift is evident in the performance of major industry players; according to Labcorp's 'Annual Report for Fiscal Year Ending 12/31, 2024' released in February 2025, the company's Biopharma Laboratory Services segment, which encompasses central laboratory and biomarker capabilities, achieved a revenue of $2,922.6 million, representing a 5.3 percent increase driven by organic demand for these complex analytical services.

Key Market Players

• Thermo Fisher Scientific, Inc.
• ICON plc
• Charles River Laboratories International, Inc.
• Covance, Inc. (Labcorp Drug Development)
• IQVIA Inc
• Syneos Health Inc
• SGS S.A.
• Intertek Group Plc
• Pace Analytical Services, LLC

Report Scope

In this report, the Global Bioanalytical Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioanalytical Testing Services Market, By Type

• Cell-based Assays
• Bacterial cell-based assays
• Viral cell-based assays
• Virology Testing
• In Vitro Virology Testing
• In Vivo Virology Testing
• Species-specific Viral PCR Assays Method Development
• Optimization and Validation
• Serology
• Immunogenicity and Neutralizing Antibodies
• Biomarker Testing
• Pharmacokinetic Testing
• Other Services

Bioanalytical Testing Services Market, By Application

• Oncology
• Neurology
• Infectious Diseases
• Gastroenterology
• Cardiology
• Other Applications

Bioanalytical Testing Services Market, By End User

• Pharmaceutical and Biopharmaceutical Companies
• Contract Development and Manufacturing Organizations
• Contract Research Organizations

Bioanalytical Testing Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioanalytical Testing Services Market.

Available Customizations:

Global Bioanalytical Testing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bioanalytical Testing Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Cell-based Assays, Bacterial cell-based assays, Viral cell-based assays, Virology Testing, In Vitro Virology Testing, In Vivo Virology Testing, Species-specific Viral PCR Assays Method Development, Optimization and Validation, Serology, Immunogenicity and Neutralizing Antibodies, Biomarker Testing, Pharmacokinetic Testing, Other Services)
  • 5.2.2. By Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology, Other Applications)
  • 5.2.3. By End User (Pharmaceutical and Biopharmaceutical Companies, Contract Development and Manufacturing Organizations, Contract Research Organizations)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Bioanalytical Testing Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bioanalytical Testing Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Bioanalytical Testing Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Bioanalytical Testing Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Bioanalytical Testing Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bioanalytical Testing Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Bioanalytical Testing Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Bioanalytical Testing Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Bioanalytical Testing Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Bioanalytical Testing Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Bioanalytical Testing Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bioanalytical Testing Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Bioanalytical Testing Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Bioanalytical Testing Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Bioanalytical Testing Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Bioanalytical Testing Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Bioanalytical Testing Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bioanalytical Testing Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Bioanalytical Testing Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Bioanalytical Testing Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Bioanalytical Testing Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bioanalytical Testing Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Bioanalytical Testing Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Bioanalytical Testing Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bioanalytical Testing Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ICON plc
• 15.3. Charles River Laboratories International, Inc.
• 15.4. Covance, Inc. (Labcorp Drug Development)
• 15.5. IQVIA Inc
• 15.6. Syneos Health Inc
• 15.7. SGS S.A.
• 15.8. Intertek Group Plc
• 15.9. Pace Analytical Services, LLC

16. Strategic Recommendations

17. About Us & Disclaimer